Opus Genetics Inc. Insider Trading

IRD

⊜ Compare

Last 12 months

Insiders bought 324K and sold 814K on the open market.

22% of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−491K

1 buy · 19 sales

Under a 10b5-1 plan

22%

of the value sold

Insiders who bought / sold

1 / 6

executives and directors

Last open-market buy

Dec 2025

Dec 29, 2025

Get an email when IRD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 23	Joseph K Schachle Chief Operating Officer	SoldNo plan	4,767	$3.57	17K	1.6%	Form 4
Oct 23	Benjamin R Yerxa President	SoldNo plan 2 parts	33,189	$3.54 average	117K	4.7%	Form 4
Oct 23	Robert E. Gagnon Chief Financial Officer	Sold10b5-1 plan	14,000	$3.55	50K	2.5%	Form 4
Oct 23	George Magrath Chief Executive Officer	SoldNo plan	9,591	$3.59	34K	0.5%	Form 4
Sep 30	Foundation Fighting Blindness Retinal Degeneration Fund Large holder	SoldNo plan	556,000	$4.96	$2.76M	15%	Form 4
Sep 3	Robert E. Gagnon Chief Financial Officer	Sold10b5-1 plan	28,000	$4.54	127K	4.8%	Form 4
Jul 23	Benjamin R Yerxa President	SoldNo plan	7,429	$2.97	22K	1.0%	Form 4
Jul 23	Joseph K Schachle Chief Operating Officer	SoldNo plan	4,644	$2.94	14K	1.6%	Form 4
Jul 23	George Magrath Chief Executive Officer	SoldNo plan	9,475	$2.95	28K	0.5%	Form 4
Jul 23	Robert E. Gagnon Chief Financial Officer	SoldNo plan	7,783	$2.95	23K	1.3%	Form 4
May 18	Foundation Fighting Blindness Retinal Degeneration Fund Large holder	SoldNo plan	1,700,000	$4.35	$7.39M	31%	Form 4
Apr 23	Benjamin R Yerxa President	SoldNo plan	7,470	$5.24	39K	1.0%	Form 4
Apr 23	Joseph K Schachle Chief Operating Officer	SoldNo plan	4,697	$5.22	25K	1.6%	Form 4
Apr 23	Rabourn Amy Zaremba Head of Fin. Quality Assurance	SoldNo plan	1,641	$5.20	9K	0.9%	Form 4
Apr 23	George Magrath Chief Executive Officer	SoldNo plan	9,511	$5.22	50K	0.5%	Form 4
Apr 23	Ashwath Jayagopal Chief Scientific & Dev. Ofc.	SoldNo plan	7,542	$5.19	39K	1.5%	Form 4
Apr 23	Robert E. Gagnon Chief Financial Officer	SoldNo plan	7,842	$5.18	41K	1.3%	Form 4
Mar 16	Joseph K Schachle Chief Operating Officer	SoldNo plan	3,719	$5.25	20K	1.2%	Form 4
Mar 16	Rabourn Amy Zaremba Head of Fin. Quality Assurance	SoldNo plan	2,816	$5.25	15K	1.5%	Form 4
Mar 16	George Magrath Chief Executive Officer	SoldNo plan	24,438	$5.21	127K	1.4%	Form 4
Mar 16	Ashwath Jayagopal Chief Scientific & Dev. Ofc.	SoldNo plan	3,719	$5.12	19K	0.7%	Form 4
Dec 29, 2025	Cam Gallagher Director	Bought 2 parts	164,000	$1.97 average	324K	8.9%	Form 4
Dec 9, 2025	Foundation Fighting Blindness Retinal Degeneration Fund Large holder	SoldNo plan	4,000,000	$2.15	$8.6M	42%	Form 4
Dec 26, 2024	George Magrath Chief Executive Officer	Bought	100,000	$0.98	98K	20%	Form 4
Nov 21, 2024	Benjamin R Yerxa President	Bought	10,000	$0.98	10K	3.0%	Form 4
Nov 15, 2024 – Nov 18, 2024	George Magrath Chief Executive Officer	Bought 2 parts	100,000	$1.01 average	101K	25%	Form 4

Oct 23No plan
Joseph K Schachle
Chief Operating Officer · sold 4,767 at $3.57
17K
1.6% of stake
Oct 23No plan
Benjamin R Yerxa
President · sold 33,189 at avg $3.54
117K
4.7% of stake
Oct 2310b5-1 plan
Robert E. Gagnon
Chief Financial Officer · sold 14,000 at $3.55
50K
2.5% of stake
Oct 23No plan
George Magrath
Chief Executive Officer · sold 9,591 at $3.59
34K
0.5% of stake
Sep 30No plan
Foundation Fighting Blindness Retinal Degeneration Fund
Large holder · sold 556,000 at $4.96
$2.76M
15% of stake
Sep 310b5-1 plan
Robert E. Gagnon
Chief Financial Officer · sold 28,000 at $4.54
127K
4.8% of stake
Jul 23No plan
Benjamin R Yerxa
President · sold 7,429 at $2.97
22K
1.0% of stake
Jul 23No plan
Joseph K Schachle
Chief Operating Officer · sold 4,644 at $2.94
14K
1.6% of stake
Jul 23No plan
George Magrath
Chief Executive Officer · sold 9,475 at $2.95
28K
0.5% of stake
Jul 23No plan
Robert E. Gagnon
Chief Financial Officer · sold 7,783 at $2.95
23K
1.3% of stake
May 18No plan
Foundation Fighting Blindness Retinal Degeneration Fund
Large holder · sold 1,700,000 at $4.35
$7.39M
31% of stake
Apr 23No plan
Benjamin R Yerxa
President · sold 7,470 at $5.24
39K
1.0% of stake
Apr 23No plan
Joseph K Schachle
Chief Operating Officer · sold 4,697 at $5.22
25K
1.6% of stake
Apr 23No plan
Rabourn Amy Zaremba
Head of Fin. Quality Assurance · sold 1,641 at $5.20
9K
0.9% of stake
Apr 23No plan
George Magrath
Chief Executive Officer · sold 9,511 at $5.22
50K
0.5% of stake
Apr 23No plan
Ashwath Jayagopal
Chief Scientific & Dev. Ofc. · sold 7,542 at $5.19
39K
1.5% of stake
Apr 23No plan
Robert E. Gagnon
Chief Financial Officer · sold 7,842 at $5.18
41K
1.3% of stake
Mar 16No plan
Joseph K Schachle
Chief Operating Officer · sold 3,719 at $5.25
20K
1.2% of stake
Mar 16No plan
Rabourn Amy Zaremba
Head of Fin. Quality Assurance · sold 2,816 at $5.25
15K
1.5% of stake
Mar 16No plan
George Magrath
Chief Executive Officer · sold 24,438 at $5.21
127K
1.4% of stake
Mar 16No plan
Ashwath Jayagopal
Chief Scientific & Dev. Ofc. · sold 3,719 at $5.12
19K
0.7% of stake
Dec 29, 2025
Cam Gallagher
Director · bought 164,000 at avg $1.97
324K
8.9% of stake
Dec 9, 2025No plan
Foundation Fighting Blindness Retinal Degeneration Fund
Large holder · sold 4,000,000 at $2.15
$8.6M
42% of stake
Dec 26, 2024
George Magrath
Chief Executive Officer · bought 100,000 at $0.98
98K
20% of stake
Nov 21, 2024
Benjamin R Yerxa
President · bought 10,000 at $0.98
10K
3.0% of stake
Nov 15, 2024 – Nov 18, 2024
George Magrath
Chief Executive Officer · bought 100,000 at avg $1.01
101K
25% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IRD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with IRD

CompareIntrinsic value

ZBIOZenas BioPharma, Inc.

$28.46+0.28%10

EVMNEvommune, Inc.

$6.04+1.68%35

PGENPrecigen Inc.

$5.06-3.71%0

ISCOInternational Stem Cell Corporation

$0.14+0.00%29

BIOABioAge Labs, Inc.

$5.95-0.17%10

HOOKHookipa Pharma Inc.

No recent price20

CBIOCrescent Biopharma, Inc.

$13.42+2.76%50

ACRSAclaris Therapeutics, Inc.

$3.68-1.60%10

Held by ETFs

IRD is in 5 US ETFs. The largest of them, with IRD's weight in each:

Spot a number that looks wrong? Check it in IRD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IRD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.